is there a shortage of glp 1 drugs GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type 2 Diabetes Care A Major GLP-1 Drug Shortage

President Trump announced drugmakers Novo Nordisk and Eli Lilly have agreed to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound.

GIP Receptor Antagonism (Blocking): Unlike many dual-agonists that activate GIP, MariTide blocks it

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

Regarding renal effects, the evidence of SGLT2is in preventing kidney failure is more abundant than for GLP-1RAs, which showed a beneficial effect on albuminuria but not on hard kidney endpoints

Designed to work naturally with your digestive system to support gut health and your bodys natural GLP-1 function

In 2024, we also saw unprecedented willingness by large numbers of patients to pay out of pocket, even in European markets, as public coverage of AOMs is still limited, at best, and more often non-existent